Journal
PHARMACOLOGICAL RESEARCH
Volume 171, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2021.105783
Keywords
Mitochondria; Diabetes; Alzheimer's disease; SS peptide; SS-31
Categories
Funding
- Alabama Agricultural Experimental Station (AAES), Hatch/Multistate Funding Program
- AAES Award for Interdisciplinary Research (AAES-AIR)
Ask authors/readers for more resources
The article discusses the pathophysiological relevance of mitochondria in Diabetes and Alzheimer's disease, as well as the potential therapeutic benefits of Szeto-Schiller-31 peptide in treating these conditions.
Diabetes and Alzheimer's disease are common chronic illnesses in the United States and lack clearly demonstrated therapeutics. Mitochondria, the powerhouse of the cell, is involved in the homeostatic regulation of glucose, energy, and reduction/oxidation reactions. The mitochondria has been associated with the etiology of metabolic and neurological disorders through a dysfunction of regulation of reactive oxygen species. Mitochondria-targeted chemicals, such as the Szeto-Schiller-31 peptide, have advanced therapeutic potential through the inhibition of oxidative stress and the restoration of normal mitochondrial function as compared to traditional antioxidants, such as vitamin E. In this article, we summarize the pathophysiological relevance of the mitochondria and the beneficial effects of Szeto-Schiller-31 peptide in the treatment of Diabetes and Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available